Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter, despite missing the company’s ...

International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the ...

Fast-food restaurant owner Yum Brands is expecting stronger sales growth this year after it moves past challenges in its Middle East markets.

Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...

The Danish pharmaceutical company expects sales growth to slow this year as capacity constraints, intensifying competition ...

Chipotle Mexican Grill said on Tuesday that if President Donald Trump's proposed tariffs on Mexico go into full effect, the ...

Chipotle reduced its financial outlook for same-store sales this year to an increase in the low to mid-single digits.

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Yum! Brands Inc. sales surpassed expectations, powered by growth at Taco Bell as the fast-food chain continues to sidestep a slowdown that has plagued many competitors.

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Be cautious ahead of Canopy Growth Corporation's FQ3 results, as weak financials and low margins may hinder stock performance ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...